Alston & Bird client Mustang Bio Inc., a clinical-stage biopharmaceutical company, has closed a public offering of common stock aimed at raising approximately $40 million.
The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes.
Based in Worcester, MA, and listed on Nasdaq, Mustang focuses on acquiring, developing, and commercializing novel immunotherapies for cancers and rare genetic diseases.
Representing Mustang in the public offering is an Alston & Bird team led by partner Mark McElreath, senior associate Gerard Hart, and associate Joel Jung (Corporate) and partner Natalie Clayton and associate Ravi Shah (Intellectual Property).
The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes.
Based in Worcester, MA, and listed on Nasdaq, Mustang focuses on acquiring, developing, and commercializing novel immunotherapies for cancers and rare genetic diseases.
Representing Mustang in the public offering is an Alston & Bird team led by partner Mark McElreath, senior associate Gerard Hart, and associate Joel Jung (Corporate) and partner Natalie Clayton and associate Ravi Shah (Intellectual Property).